Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 1.66% is 61% below its 5-year average of 4.26%, near the high end of its 5-year range (-42.27%–8.66%).
62.71% below its 12-month average of 4.45%.
Reported quarterly EBITDA margin; no daily interpolation. Q3 FY2026 (2026-07-31): 8.66%.
EBITDA MARGIN
1.66%
EBITDA MARGIN AVG TTM
4.45%
EBITDA MARGIN AVG 3Y
6.27%
EBITDA MARGIN AVG 5Y
4.26%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-62.71%
CURRENT VS 3Y AVG
-73.54%
CURRENT VS 5Y AVG
-61.00%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$236.14M
EBITDA Margin
-43.93%
TTM Avg
-56.69%
3Y Avg
-115.93%
5Y Avg
-139.79%
Market Cap
$235.40M
EBITDA Margin
-1029.09%
TTM Avg
-1029.09%
3Y Avg
-1029.09%
5Y Avg
-1029.09%
Market Cap
$240.09M
EBITDA Margin
-163095.33%
TTM Avg
-97357.05%
3Y Avg
-88166.59%
5Y Avg
-88166.59%
Market Cap
$234.28M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$240.66M
EBITDA Margin
-1441.45%
TTM Avg
-4661.83%
3Y Avg
-5918.79%
5Y Avg
-3944.51%
Market Cap
$240.82M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
Market Cap
$243.81M
EBITDA Margin
6.37%
TTM Avg
-0.39%
3Y Avg
-2.45%
5Y Avg
1.13%
Market Cap
$243.66M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| High Tide Inc. (HITI) | $237.25M | 1.66% | 4.45% | 6.27% | 4.26% |
| MacroGenics, Inc. (MGNX)vs › | $236.14M | -43.93% | -56.69% | -115.93% | -139.79% |
| BioAge Labs Inc. (BIOA)vs › | $235.40M | -1029.09% | -1029.09% | -1029.09% | -1029.09% |
| InflaRx N.V. (IFRX)vs › | $240.09M | -163095.33% | -97357.05% | -88166.59% | -88166.59% |
| Biodesix, Inc. (BDSX)vs › | $234.28M | -25.05% | -32.88% | -63.97% | -61.52% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.66M | -1441.45% | -4661.83% | -5918.79% | -3944.51% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $240.82M | 10.49% | 1.20% | -4.19% | -40.04% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | 6.37% | -0.39% | -2.45% | 1.13% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $243.34M | N/A | N/A | N/A | N/A |
Gross Margin
25.9%
EBITDA Margin
1.7%
Operating Margin
0.6%
Net Margin
-4.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-07-31 | 8.66% |
| 2026-04-30 | 7.94% |
| 2026-01-31 | 6.82% |
| 2025-10-31 | -7.73% |
| 2025-07-31 | 6.56% |
| 2025-04-30 | 4.94% |
| 2025-01-31 | 4.15% |
| 2024-10-31 | 1.83% |
| 2024-07-31 | 6.63% |
| 2024-04-30 | 7.64% |
| 2024-01-31 | 7.53% |
| 2023-10-31 | -20.16% |
| 2023-07-31 | 6.30% |
| 2023-04-30 | 4.28% |
| 2023-01-31 | 3.44% |
| 2022-10-31 | -42.27% |
| 2022-07-31 | 2.63% |
| 2022-04-30 | 0.06% |
| 2022-01-31 | 1.33% |
| 2021-10-31 | -6.30% |
| 2021-07-31 | 2.15% |
| 2021-04-30 | 7.84% |
| 2021-01-31 | 10.57% |
| 2020-10-31 | 8.75% |
| 2020-07-31 | 14.09% |
| 2020-04-30 | 8.27% |
| 2020-01-31 | -6.18% |
| 2019-10-31 | -53.77% |
| 2019-07-31 | -43.30% |
| 2019-04-30 | -61.80% |
| 2019-01-31 | -93.48% |
| 2018-10-31 | -142.20% |
| 2018-07-31 | -32.05% |
| 2018-04-30 | -45.85% |
| 2018-01-31 | 17.35% |
| 2017-10-31 | 12.51% |
| 2017-07-31 | 26.35% |
